Skip to main content
ELAN
NYSE Life Sciences

Elanco Q2 Revenue Jumps 10% to $1.37B, Raises Full-Year Guidance

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$27.14
Mkt Cap
$12.786B
52W Low
$13.75
52W High
$27.72
52W Position info
97% above low
Off High info
2.1% below high
Rel. Volume info
1.5× avg
Market data snapshot near publication time

ELAN sits 97% above its 52-week low of $13.75.

Summary

Elanco reported Q2 2026 revenue of $1.37 billion, a 10% increase, and raised full-year guidance. New product launches and the AHV acquisition are driving growth, while restructuring efforts promise future margin expansion.


Key Events · Earnings and Guidance · ELAN

  • Q2 Revenue +10% to $1.37B

    Revenue rose 10% year-over-year to $1.37 billion, driven by new products Zenrelia and Credelio Quattro, and strong farm animal performance.

  • Full-Year Guidance Raised

    Management increased full-year 2026 guidance for revenue ($5.09B–$5.14B), Adjusted EBITDA, and Adjusted EPS, reflecting confidence in commercial momentum.

  • AHV Acquisition Completed

    Acquired AHV International B.V. for $243 million on April 30, 2026, adding farm animal health solutions and expanding the cattle portfolio in Europe and the U.S.

  • Befrena Launch Underway

    Initiated phased launch of Befrena (tirnovetmab), a new anti-IL-31 monoclonal antibody for canine allergic dermatitis, during Q2 2026.


Analysis · ELAN · Life Sciences

Elanco delivered a strong Q2 with revenue up 10% year-over-year to $1.37 billion, driven by new product launches like Zenrelia and Credelio Quattro. Net income swung to $54 million from $11 million a year ago. Management raised full-year guidance for revenue, Adjusted EBITDA, and Adjusted EPS, signaling confidence in the product pipeline and commercial execution. The quarter also saw the completion of the AHV acquisition, expanding the farm animal portfolio, and the phased launch of Befrena, a new canine dermatitis treatment. Restructuring charges are on track, with expected savings ramping in 2027. The stock is trading near its 52-week high, reflecting market optimism around the turnaround story.

At the time of this filing, ELAN was trading at $27.14 on NYSE in the Life Sciences sector, with a market capitalization of approximately $12.8B. The 52-week trading range was $13.75 to $27.72. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ELAN - Latest Insights

ELAN
Aug 05, 2026, 6:27 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $25.80
Real-time Price: $27.14 info
Change: +$1.34 (+5%) info
Market Cap: $12.786B info
ELAN
Aug 05, 2026, 6:27 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $25.80
Real-time Price: $27.14 info
Change: +$1.34 (+5%) info
Market Cap: $12.786B info
ELAN
Jun 04, 2026, 1:47 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $24.94
Real-time Price: $27.14 info
Change: +$2.21 (+9%) info
Market Cap: $12.786B info
ELAN
Jun 04, 2026, 6:26 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $23.40
Real-time Price: $27.14 info
Change: +$3.74 (+16%) info
Market Cap: $12.786B info
ELAN
May 18, 2026, 7:27 AM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $19.84
Real-time Price: $27.14 info
Change: +$7.30 (+37%) info
Market Cap: $12.786B info